Search
Seres Therapeutics Inc
MCRBAdd to Watchlist
1.830USD
+0.060+3.39%
Close 11-02 16:00（ET）
18.19MMarket Cap
LossP/E TTM
Seres Therapeutics Inc (MCRB) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Seres Therapeutics Inc in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
17.000USD+849.72%
MCRB Analyst Recommendation Trends
In the current month, MCRB has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MCRB average Analyst price target in the last month is 17.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
2
2
2
2
2
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
1
1
1
MCRB Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
Financial Forecasting
Based on analysts' estimates, MCRB EPS is projected to reach -1.005 in FY2026Q3, following reported EPS of 0.472 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-2.11
-1.88
-2.19
-1.00
-1.01
Actual
-1.66
-2.08
0.47
--
--
Surprise
+21.26%
-10.53%
+121.60%
--
--
FAQs
What is Seres Therapeutics Inc's expected revenue for the next quarter?
Seres Therapeutics Inc's expected revenue is 6.35M.
What is Seres Therapeutics Inc's price target?
Analysts forecast that Seres Therapeutics Inc's price target is USD 17.00, with the highest forecast at USD 22.00 and the lowest forecast at USD 12.00.
How have Seres Therapeutics IncMCRB's recent earnings per share performed?
The market expectation was USD 0.47, while Seres Therapeutics IncMCRB's earnings per share (EPS) for the previous quarter was USD -2.08. EPS for the next quarter is expected at USD -1.00.
What is the analyst rating for Seres Therapeutics Inc?
Based on the ratings of Seres Therapeutics Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.